COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Phase 2
Terminated
NCT05000216
| Condition | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Pemphigus Vulgaris, Multiple Sclerosis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| Status | Terminated |
|---|
| Enrollment | 258 participants |
|---|
| Interventions | Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX) |
|---|
| Start date | Aug 13, 2021 |
|---|
| Completion date | Jun 22, 2023 |
|---|
| Results posted | Aug 22, 2025 |
|---|
Summary
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: * Systemic Lupus Erythematosus (SLE) * Rheumatoid Arthritis (RA) * Multiple Sclerosis (MS) * Systemic Sclerosis (SSc), and * Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: * Systemic Lupus Erythematosus (SLE) * Juvenile Idiopathic Arthritis (JIA) * Pediatric-Onset Multiple Sclerosis (POMS) * Juvenile Dermatomyositis (JDM)
Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | NA Percentage of participants |
|---|
Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2: Alternative mRNA + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort D, Arm D4: Sanofi-GSK + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2: Alternative mRNA + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort E, Arm E4: Sanofi-GSK + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort F, Arm F2: Alternative mRNA + Withhold IS (BCDT) | NA Percentage of participants |
|---|
| Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (BCDT) | NA Percentage of participants |
|---|
Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.